RBC Bioscience

RBC Bioscience Gross Margin

The Gross Margin of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 47.78 %. In the previous year, Gross Margin was 42.27 % — a change of 13.05% (higher).

Gross Margin

47.78 %

YoY

13.05%

Last updated:

Gross Margin of RBC Bioscience is 2024 47.78 % . Gross Margin of RBC Bioscience was 2023 42.27 % . It decreases by 13.05% higher compared to the previous year.

RBC Bioscience's gross margin stands at 47.8%, down from 52.2% several years earlier.

The RBC Bioscience Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
45.35 TWD
Jan 1, 2019
41.38 TWD
Jan 1, 2020
52.22 TWD
Jan 1, 2021
46.61 TWD
Jan 1, 2022
41.98 TWD
Jan 1, 2023
42.27 TWD
Jan 1, 2024
47.78 TWD
The RBC Bioscience Gross Margin history
YEARGross MarginYoY
47.78 %+13.05%
42.27 %+0.67%
41.98 %-9.92%
46.61 %-10.74%
52.22 %+26.20%
41.38 %-8.77%
45.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Gross Margin of RBC Bioscience is 47.78 % in 2024.

Gross Margin of RBC Bioscience changed from 42.27 % to 47.78 %, representing a 13.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RBC Bioscience

All Key Metrics — RBC Bioscience